Taro Pharmaceutical Industries
WKN: 897505 / ISIN: IL0010827181897505 -48% ????
hat die irgendjemand auf der watchlist?
Deshalb kaufe ich nur noch Biotechs die noch weiter von Medikamenteneinführungen weg sind. Ist einfach weniger riskant.
by the way affymetrix scheint ja wieder zu kommen...
Taro Pharmaceuticals meldet Zahlen für das Dezember-Quartal 2018
- 2018 Dec-Q Umsatz ~176 Mio. $
- 2018 Dec-Q Gewinn ~94 Mio. $
- 9M/2018 Umsatz ~490 Mio. $
- 9M/2018 Gewinn ~223 Mio. $
- EPS 5,71$
- EPS 5,71$
http://phx.corporate-ir.net/...&p=irol-newsArticle&ID=2386458
Taro Pharmaceuticals Zahlen für Q2/19
- Umsätze 161 Mio. $
- Gewinn 66 Mio. $
Mr. Uday Baldota, Taro’s CEO stated, “Operating results of this quarter reflect the impact of many underlying challenges of our industry. Despite the headwinds, we remain steadfast in our commitment to customers and patients. We are executing on our strategy and continue to add to our portfolio of high quality products across business and markets.”
https://taro.gcs-web.com/news-releases/...-quarter-ended-june-30-2019
Zahlen für Q4/19
- Umsatz 148 Mio. $
- Gewinn 68 Mio. $
- EPS 1,76$
Zahlen für 9M/2019
- Umsatz 470 Mio. $
- Gewinn 190 Mio. $
- EPS 4,93$
Mr. Uday Baldota, Taro’s CEO, stated, “Despite approximately 75% of our products ranking in the top two (2) ─ when measured on market share ─ this quarters’ financial performance reflects, in big measure, the continued challenging market dynamics particularly in the U.S. generic market. Responding to the faith our customers and patients repose in us, we continue to invest in R&D for augmenting our product offering. This, coupled with investments in inorganic strategic opportunities, is aimed toward creating longer term shareholder value.”
https://taro.gcs-web.com/news-releases/...es-results-december-31-2019
Zahlen für das März-Quartal 2020
- Umsatz 175 Mio. $
- Gewinn 54 Mio. $
- EPS 1.42$
FY 2020
- Umsatz 645 Mio. $
- Gewinn 244 Mio. $
- EPS 6.35$
"Mr. Uday Baldota, Taro’s CEO, stated, “Despite the leading market position of many of our products, we continue to face a challenging U.S. generic market. In the short-term, even as we commercialize recently approved products, we expect operations and profitability to be temporarily impacted as a result of the COVID-19 pandemic—now more than ever, we continue to focus on better serving the needs of our customers and patients. We continue to concentrate on creating shareholder value by continuing our R&D investment, as well as exploring investments in inorganic strategic opportunities."
https://taro.gcs-web.com/news-releases/...ts-year-ended-march-31-2020
Zahlen für das Juni-Quartal 2020
- Umsatz 118 Mio. $
Taro Achieves Global Resolution of DOJ Antitrust Investigations
On July 23, 2020, Taro Pharmaceuticals U.S.A., Inc. (“Company”), globally resolved all matters related to the Company in connection with the multi-year investigations by the Department of Justice, Antitrust Division and Civil Division (“DOJ”) into the U.S. generic pharmaceutical industry. Under a Deferred Prosecution Agreement reached with DOJ Antitrust, the DOJ will file an Information for conduct that took place between 2013 and 2015. If the Company adheres to the terms of the agreement, including the payment of $205.7 million, the DOJ will dismiss the Information at the end of a three-year period. The Company has also reached a framework understanding with DOJ Civil, subject to final agreement and agency authorization, in which the Company has agreed to pay $213.3 million to resolve all claims related to federal healthcare programs. Accordingly, a charge of $418.9 million is taken in the current quarter and shown as Settlements and loss contingencies.
https://taro.gcs-web.com/news-releases/...-quarter-ended-june-30-2020
Zahlen für das Sept-Quartal 2020
- Umsatz 143 Mio. $
- Gewinn 45 Mio. $
- EPS 1,18$
https://taro.gcs-web.com/news-releases/...s-results-september-30-2020
Zahlen für das Dez-Quartal 2020
- Umsatz 140 Mio. $
- Gewinn 33 Mio. $
- EPS 0,86$
https://taro.gcs-web.com/news-releases/...es-results-december-31-2020
Zahlen für das Sept-Q 2021
- Umsatz 132 Mio. $
- Gewinn 23 Mio. $
- EPS 0,62$
https://taro.gcs-web.com/news-releases/...s-results-september-30-2021
Zahlen für das Dez-Q 2021
- Umsatz 139 Mio. $
- Gewinn 26 Mio. $
- EPS 0,70$
https://taro.gcs-web.com/news-releases/...es-results-december-31-2021
Zahlen für das Juni-Quartal 2022
- Umsatz 157 Mio. $
- Gewinn 14 Mio. $
- EPS 0,37$
Herr Uday Baldota, CEO von Taro, erklärte: „Obwohl wir die führende Marktposition vieler unserer Produkte behaupten, sehen wir uns weiterhin einem allgemeinen Markttrend gegenüber, insbesondere in den USA, der sich nicht dramatisch ändert, und je nach Produkt, Die Preisdeflation bleibt eine Herausforderung. Da die Inputkosten stark steigen, werden wir weiterhin steigende Kapitalbeträge, einschließlich F&E-Bemühungen, in wachstumsstarke und profitable Unternehmen und neue Geschäftsmöglichkeiten investieren.“
https://taro.gcs-web.com/news-releases/...-quarter-ended-june-30-2022
Zahlen für das September-Quartal 2022
- Umsatz 130 Mio. $
- Verlust 3 Mio. $
- EPS -0,07$
https://taro.gcs-web.com/news-releases/...s-results-september-30-2022